Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Molecular Partners AG    MOLN   CH0256379097

MOLECULAR PARTNERS AG (MOLN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
24.5(c) 24(c) 23(c) 23(c) 23.7 Last
27 648 16 540 4 051 19 543 9 006 Volume
+0.20% -2.04% -4.17% 0.00% +3.04% Change
More quotes
Financials (CHF)
Sales 2018 29,8 M
EBIT 2018 -24,5 M
Net income 2018 -25,7 M
Finance 2018 106 M
Yield 2018 -
Sales 2019 31,1 M
EBIT 2019 -30,8 M
Net income 2019 -31,6 M
Finance 2019 64,1 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 12,8x
EV / Sales2019 13,6x
Capitalization 487 M
More Financials
Company
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders.It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to... 
More about the company
Surperformance© ratings of Molecular Partners AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MOLECULAR PARTNERS AG
06/21Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Mich..
TE
06/21MOLECULAR PARTNERS AG : Molecular Partners Appoints Pamela A. Trail as Chief Sci..
AC
06/21MOLECULAR PARTNERS : Appoints Pamela A. Trail as Chief Scientific Officer; Micha..
AQ
06/15Molecular Partners presents updated results from its ongoing Phase 2 combinat..
TE
06/15MOLECULAR PARTNERS AG : Molecular Partners Presents Updated Results From its Ong..
AC
05/16Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meetin..
TE
05/16MOLECULAR PARTNERS AG : Molecular Partners to Present Final MP0250 Phase 1 Data ..
AC
04/26Further MP0250 clinical data and partner interest underline Molecular Partner..
TE
04/26MOLECULAR PARTNERS : Further MP0250 clinical data and partner interest underline..
AQ
04/26MOLECULAR PARTNERS AG : Further MP0250 Clinical Data and Partner Interest Underl..
AC
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/21At Molecular Partners, Trail will apply experience gained in these positions .. 
06/21AdoRx raises $10M for adenosine program in cancer; Molecular Partners poaches..
2
06/21Molecular Partners names Regeneron cancer leader as CSO in reshuffle of leade.. 
06/15Molecular Partners says 5 of 8 patients responded in multiple myeloma trial  
05/16Molecular Partners AG : Molecular Partners to Present Final MP0250 Phase 1 Da.. 
More tweets
Qtime:21
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MOLN | CH0256379097 | 4-Traders
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 39,6  CHF
Spread / Average Target 72%
EPS Revisions
Managers
NameTitle
Patrick Amstutz Chief Executive Officer & Director
William Matt Burns Chairman
Michael Tobias Stumpp Chief Operating Officer
Andreas Emmenegger Chief Financial Officer
Andreas Harstrick Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR PARTNERS AG-12.55%521
GILEAD SCIENCES8.01%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.49%10 457
NEUROCRINE BIOSCIENCES, INC.32.61%9 250